Aranesp extended dosing sBLA
This article was originally published in Pharmaceutical Approvals Monthly
Amgen submits an sBLA for use of Aranesp (darbepoetin alfa) every three weeks for chemotherapy-induced anemia in patients with non-myeloid malignancies. Labeling currently recommends a weekly dosing schedule...
You may also be interested in...
Fresenius Kabi must pay Eli Lilly €28m in damages after a French court of first instance found that the generics firm’s pemetrexed infringed intellectual property protecting the Alimta chemotherapy brand. The German firm has commented on possible next steps.
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Meeting to address opioid abuse crisis was also a trial of whether FDA could conduct important public business using online-only technology.